Moro M - Search Results

1

Vaccination with mouse mammary adenocarcinoma cells coexpressing B7-1 (CD80) and B7-2 (CD86) discloses the dominant effect of B7-1 in the induction of antitumor immunity.

Martín-Fontecha A, Moro M, Crosti MC, Veglia F, Casorati G, Dellabona P. Martín-Fontecha A, et al. Among authors: moro m. J Immunol. 2000 Jan 15;164(2):698-704. doi: 10.4049/jimmunol.164.2.698. J Immunol. 2000. PMID: 10623812

2

Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules.

Moro M, Gasparri AM, Pagano S, Bellone M, Tornaghi P, Veglia F, Corti A, Casorati G, Dellabona P. Moro M, et al. Cancer Res. 1999 Jun 1;59(11):2650-6. Cancer Res. 1999. PMID: 10363988

3

Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.

Bellone M, Cantarella D, Castiglioni P, Crosti MC, Ronchetti A, Moro M, Garancini MP, Casorati G, Dellabona P. Bellone M, et al. Among authors: moro m. J Immunol. 2000 Sep 1;165(5):2651-6. doi: 10.4049/jimmunol.165.5.2651. J Immunol. 2000. PMID: 10946294

4

IL-21 is a central memory T cell-associated cytokine that inhibits the generation of pathogenic Th1/17 effector cells.

Kastirr I, Maglie S, Paroni M, Alfen JS, Nizzoli G, Sugliano E, Crosti MC, Moro M, Steckel B, Steinfelder S, Stölzel K, Romagnani C, Botti F, Caprioli F, Pagani M, Abrignani S, Geginat J. Kastirr I, et al. Among authors: moro m. J Immunol. 2014 Oct 1;193(7):3322-31. doi: 10.4049/jimmunol.1400775. Epub 2014 Aug 29. J Immunol. 2014. PMID: 25172491 Clinical Trial.

5

Signal Strength and Metabolic Requirements Control Cytokine-Induced Th17 Differentiation of Uncommitted Human T Cells.

Kastirr I, Crosti M, Maglie S, Paroni M, Steckel B, Moro M, Pagani M, Abrignani S, Geginat J. Kastirr I, et al. Among authors: moro m. J Immunol. 2015 Oct 15;195(8):3617-27. doi: 10.4049/jimmunol.1501016. Epub 2015 Sep 16. J Immunol. 2015. PMID: 26378072

6

Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor alpha in mouse models.

Gasparri A, Moro M, Curnis F, Sacchi A, Pagano S, Veglia F, Casorati G, Siccardi AG, Dellabona P, Corti A. Gasparri A, et al. Among authors: moro m. Cancer Res. 1999 Jun 15;59(12):2917-23. Cancer Res. 1999. PMID: 10383155

7

CD28 and LFA-1 contribute to cyclosporin A-resistant T cell growth by stabilizing the IL-2 mRNA through distinct signaling pathways.

Geginat J, Clissi B, Moro M, Dellabona P, Bender JR, Pardi R. Geginat J, et al. Among authors: moro m. Eur J Immunol. 2000 Apr;30(4):1136-44. doi: 10.1002/(SICI)1521-4141(200004)30:4<1136::AID-IMMU1136>3.0.CO;2-3. Eur J Immunol. 2000. PMID: 10760803 Free article.

8

Generation of functional HLA-DR*1101 tetramers receptive for loading with pathogen- or tumour-derived synthetic peptides.

Moro M, Cecconi V, Martinoli C, Dallegno E, Giabbai B, Degano M, Glaichenhaus N, Protti MP, Dellabona P, Casorati G. Moro M, et al. BMC Immunol. 2005 Dec 5;6:24. doi: 10.1186/1471-2172-6-24. BMC Immunol. 2005. PMID: 16329759 Free PMC article.

9

Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha.

Moro M, Pelagi M, Fulci G, Paganelli G, Dellabona P, Casorati G, Siccardi AG, Corti A. Moro M, et al. Cancer Res. 1997 May 15;57(10):1922-8. Cancer Res. 1997. PMID: 9157986

10

Use of MHC class II tetramers to investigate CD4+ T cell responses: problems and solutions.

Cecconi V, Moro M, Del Mare S, Dellabona P, Casorati G. Cecconi V, et al. Among authors: moro m. Cytometry A. 2008 Nov;73(11):1010-8. doi: 10.1002/cyto.a.20603. Cytometry A. 2008. PMID: 18612991 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,224 results

Search Page

Filters